Full Press Release Details
cph8kex991090606.txt
PRESS RELEASE DATED AUGUST 15, 2006
Crocker Coulson Donald Xu
President Vice President, Strategic Planning
CCG Elite China Pharma Holdings, Inc.
310 231-8600 ext 103 858-776-8880
China Pharma Holdings, Inc.
Provides Preliminary 2007 Outlook
HAIKOU CITY, Hainan Province, PRC - September 20, 2006 - China Pharma Holdings,
Inc. ("China Pharma") (OTC BB: CPHI.OB) today provided a preliminary outlook for
its 2007 financial results.
The Company previously announced that it expects to achieve revenues of $20
million and net income of $8 million for the year ending December 31, 2006. The
Company expects net income to increase by at least 30% for 2007 from 2006
levels. This guidance is based on recent new drug introductions and strong
pipeline development.
"China Pharma's strategy of growth through aggressive new product launches and
strong research and development provides us confidence that we will sustain
improved net income for 2007. Recent product launches include Propylgallate and
Ozagrel, which treat cardiovascular & cerebrovascular conditions, the first and
third leading causes of death in China, respectively," commented Li Zhi Lin,
About China Pharma Holdings, Inc.
China Pharma Holdings, Inc. develops, manufactures, and markets generic and
brand bio-pharmaceutical products in China that treat a wide range of
conditions, including infections, hepatitis, vascular, CNS and other prevailing
diseases. Helpson Bio-pharmaceutical Co., Ltd (Helpson), a specialty
bio-pharmaceutical company headquartered in Haikou City, Hainan province in
China, is a wholly owned subsidiary of China Pharma Holdings, Inc.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of
1995: Any statements set forth above that are not historical facts are
forward-looking statements that involve risks and uncertainties that could cause
actual results to differ materially from those in the forward-looking
statements, which may include, but are not limited to, such factors as
unanticipated changes in product demand, increased competition, failure to
obtain or maintain intellectual property protection, downturns in the Chinese
economy, uncompetitive levels of research and development, failure to obtain
regulatory approvals, and other information detailed from time to time in the
Company's filings and future filings with the United States Securities and
Exchange Commission.